|
 It said it would study combining ponesimod and dimethyl fumarate (Tecfidera)
for patients with RMS. The POINT study will be conducted under a
Special Protocol Assessment agreement with the U.S. Food and Drug
Administration.
"Despite recent advances in the treatment of RMS, there remains a
considerable medical need for improved long-term disease control
without compromising patient safety. While combination therapy is a
logical next step, it has likely been limited due to the potential
risks associated with the longduration of action of existing
products," it said on Thursday.
(Reporting by Michael Shields, edited by John Revill)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
